Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity

被引:92
作者
Etienne, MC
Ilc, K
Formento, JL
Laurent-Puig, P
Formento, P
Cheradame, S
Fischel, JL
Milano, G
机构
[1] Ctr Antoine Lacassagne, Oncopharmacol Unit, F-06189 Nice 2, France
[2] INSERM, U490, Unite Toxicol Mol, F-75270 Paris 06, France
关键词
thymidylate synthase; methylenetetrahydrofolate reductase; pharmacogenetics; gene polymorphism; 5-fluorouracil; fluoropyrimidine;
D O I
10.1038/sj.bjc.6601523
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship of thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms on 5-fluorouracil (FU) sensitivity was tested on 19 human cancer cell lines (head and neck, breast, digestive tract) in the absence and presence of folinic acid (FA) supplementation. Thymidylate synthase polymorphisms in the 5' promoter region (double or triple tandem repeats) and 3' untranslated region (6-bp deletion) were analysed by PCR. The C677T and A1298C MTHFR polymorphisms were determined by melting curve analyses (LightCycler). Thymidylate synthase activity and intracellular concentration of the reduced folate 5-10 methylenetetrahydrofolate (CH2FH4) were measured (biochemical assays). Thymidylate synthase activity was significantly different according to 5' TS genotype, heterozygous cell lines (2R/3R) exhibiting higher TS activities than homozygous ones (P = 0.05). However, whether in the absence or presence of FA, FU sensitivity was not statistically associated with either 5' or 3' TS polymorphism. Basal CH2FH4 cellular concentrations were lowest in C677T homozygous wild-type (wt) (C/C) cell lines. FU sensitivity was not linked to C677T polymorphism. In contrast, there was a marked trend for a greater FU efficacy in mutated A1298C variants (C/C+A/C) as compared to wt homozygous cell lines (A/A) (P=0.055 and 0.085 without and with FA supplementation, respectively). These results suggest for the first time a potential role of A1298C MTHFR polymorphism on fluoropyrimidine sensitivity.
引用
收藏
页码:526 / 534
页数:9
相关论文
共 42 条
[1]   A ROLE FOR DIHYDROPYRIMIDINE DEHYDROGENASE AND THYMIDYLATE SYNTHASE IN TUMOR SENSITIVITY TO FLUOROURACIL [J].
BECK, A ;
ETIENNE, MC ;
CHERADAME, S ;
FISCHEL, JL ;
FORMENTO, P ;
RENEE, N ;
MILANO, G .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (10) :1517-1522
[2]  
BUNNI M, 1988, CANCER RES, V48, P3398
[3]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[4]   Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients [J].
Cheradame, S ;
Etienne, MC ;
Formento, P ;
Schneider, M ;
Dassonville, O ;
Demard, F ;
Milano, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2604-2610
[5]   Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: Experimental data [J].
Cheradame, S ;
Etienne, MC ;
Chazal, M ;
Guillot, T ;
Fischel, JL ;
Formento, P ;
Milano, G .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (06) :950-959
[6]   EFFECT OF 5,10-METHYLENETETRAHYDROFOLATE ON DISSOCIATION OF 5-FLUORO-2'-DEOXYURIDYLATE FROM THYMIDYLATE SYNTHETASE - EVIDENCE FOR AN ORDERED MECHANISM [J].
DANENBERG, PV ;
DANENBERG, KD .
BIOCHEMISTRY, 1978, 17 (19) :4018-4024
[7]   PROSPECTIVE RANDOMIZED COMPARISON OF FLUOROURACIL VERSUS FLUOROURACIL AND HIGH-DOSE CONTINUOUS INFUSION LEUCOVORIN CALCIUM FOR THE TREATMENT OF ADVANCED MEASURABLE COLORECTAL-CANCER IN PATIENTS PREVIOUSLY UNEXPOSED TO CHEMOTHERAPY [J].
DOROSHOW, JH ;
MULTHAUF, P ;
LEONG, L ;
MARGOLIN, K ;
LITCHFIELD, T ;
AKMAN, S ;
CARR, B ;
BERTRAND, M ;
GOLDBERG, D ;
BLAYNEY, D ;
ODUJINRIN, O ;
DELAP, R ;
SHUSTER, J ;
NEWMAN, E .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :491-501
[8]   Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy:: Phenotypic and genotypic analyses [J].
Etienne, MC ;
Chazal, M ;
Laurent-Puig, P ;
Magné, N ;
Rosty, C ;
Formento, JL ;
Francoual, M ;
Formento, P ;
Renée, N ;
Chamorey, E ;
Bourgeon, A ;
Seitz, JF ;
Delpero, JR ;
Letoublon, C ;
Pezet, D ;
Milano, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2832-2843
[9]   A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].
FROSST, P ;
BLOM, HJ ;
MILOS, R ;
GOYETTE, P ;
SHEPPARD, CA ;
MATTHEWS, RG ;
BOERS, GJH ;
DENHEIJER, M ;
KLUIJTMANS, LAJ ;
VANDENHEUVEL, LP ;
ROZEN, R .
NATURE GENETICS, 1995, 10 (01) :111-113
[10]   Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients:: 10-year follow-up results of the French Adjuvant Study Group 01 trial [J].
Fumoleau, P ;
Kerbrat, P ;
Romestaing, P ;
Fargeot, P ;
Brémond, A ;
Namer, M ;
Schraub, S ;
Gaudier, MJ ;
Mihura, J ;
Monnier, A ;
Clavère, P ;
Serin, D ;
Seffert, P ;
Pourny, C ;
Facchini, T ;
Jacquin, JP ;
Sztermer, JF ;
Datchary, J ;
Ramos, R ;
Luporsi, E .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :298-305